Adamis Pharmaceuticals Corp (NASDAQ:ADMP) was down 5.5% on Thursday . The stock traded as low as $4.06 and last traded at $4.30. Approximately 786,248 shares traded hands during mid-day trading, an increase of 7% from the average daily volume of 731,558 shares. The stock had previously closed at $4.55.
Several equities research analysts have weighed in on ADMP shares. B. Riley reaffirmed a “buy” rating and issued a $9.50 price target on shares of Adamis Pharmaceuticals in a research note on Wednesday, October 4th. Zacks Investment Research cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, November 20th. ValuEngine cut shares of Adamis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, October 3rd. Raymond James Financial began coverage on shares of Adamis Pharmaceuticals in a report on Tuesday, September 12th. They set an “outperform” rating and a $7.00 price target on the stock. Finally, Maxim Group set a $14.00 price target on shares of Adamis Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, December 5th. Two research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. The stock currently has a consensus rating of “Hold” and an average price target of $10.33.
The company has a debt-to-equity ratio of 0.06, a current ratio of 3.93 and a quick ratio of 3.79.
A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its stake in shares of Adamis Pharmaceuticals by 22.2% in the 2nd quarter. Vanguard Group Inc. now owns 942,940 shares of the specialty pharmaceutical company’s stock valued at $4,903,000 after purchasing an additional 171,167 shares in the last quarter. EAM Investors LLC increased its stake in shares of Adamis Pharmaceuticals by 58.3% in the 3rd quarter. EAM Investors LLC now owns 371,732 shares of the specialty pharmaceutical company’s stock worth $1,942,000 after acquiring an additional 136,970 shares in the last quarter. Leisure Capital Management increased its stake in Adamis Pharmaceuticals by 7.2% during the 2nd quarter. Leisure Capital Management now owns 145,909 shares of the specialty pharmaceutical company’s stock valued at $759,000 after purchasing an additional 9,832 shares in the last quarter. Granite Investment Partners LLC bought a new stake in Adamis Pharmaceuticals during the 3rd quarter valued at about $457,000. Finally, Advisor Group Inc. increased its stake in Adamis Pharmaceuticals by 149.9% during the 3rd quarter. Advisor Group Inc. now owns 56,001 shares of the specialty pharmaceutical company’s stock valued at $292,000 after purchasing an additional 33,591 shares in the last quarter. 16.61% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Adamis Pharmaceuticals (ADMP) Shares Down 5.5%” was originally published by Transcript Daily and is the property of of Transcript Daily. If you are viewing this news story on another site, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The original version of this news story can be viewed at https://transcriptdaily.com/2017/12/22/adamis-pharmaceuticals-admp-shares-down-5-5.html.
About Adamis Pharmaceuticals
Adamis Pharmaceuticals Corporation is a pharmaceutical company. The Company is engaged in the development of its specialty pharmaceutical products. The Company is developing various products in the allergy and respiratory markets, including a dry powder inhaler technology that it acquired from 3M Company (3M).
Receive News & Ratings for Adamis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.